• ქართული
  • English
  • Bristol-Myers plans to divest Celgene's psoriasis drug

    Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp’s psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.

    Market Quotes by TradingView